[Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma].
To explore the effects of proteasome inhibitor PS-341 on the cytokine expressions of mesenchymal stem cells (MSC) in patients with multiple myeloma (MM), MSCs of 11 patients were cultured in medium of RPMI 1640 containing 10% FBS. When cells grew to 5 x 10(5) - 1 x 10(6), cells were exposed to 50 nmol/L PS-341 for 4 hours, then harvested. The expressions of IL-6, IL-1beta and SCF were detected by RT-PCR. The results indicated that after treatment with PS-341 the expressions of IL-6, IL-1beta and SCF of MSCs decreased markedly, especially that of IL-1beta, compared with control (P < 0.05, P < 0.01, P < 0.05, respectively). There were obviously differences of IL-1beta expression between refractory/relapsed group and complete remission (CR) group and IL-1beta expression was inhibited more seriously in CR group, whereas there were no significant differences of IL-6 and SCF expression between two groups; IL-1beta expression of patients treated with PS-341 was not detected; there were not effects of IL-1beta expression on expressions of IL-6 and SCF. It is concluded that proteasome inhibitor PS-341 downregulated the expressions of IL-6, IL-1beta and SCF of MSCs in patients with MM.
Lin
Ru-Feng
RF
Department of Hematology, The First Affiliated Hospital of Nanjing Medical Univercity, Nanjing 210029, China.
Lu
Hua
H
Liu
Peng
P
Shen
Wen-Yi
WY
Zhang
Jian-Fu
JF
Wu
Yu-Jie
YJ
Fei
Xiao-Ming
XM
Li
Jian-Yong
JY
D000970:Antineoplastic Agents / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000378:metabolism* / Q000473:pathology; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D016207:Cytokines / Q000096:biosynthesis*; D006801:Humans; D053583:Interleukin-1beta / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D009101:Multiple Myeloma / Q000378:metabolism* / Q000473:pathology; D011480:Protease Inhibitors / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology*; D019089:Stem Cell Factor / Q000096:biosynthesis
D000970:Antineoplastic Agents; D001897:Boronic Acids; D016207:Cytokines; D053583:Interleukin-1beta; D015850:Interleukin-6; D011480:Protease Inhibitors; D011719:Pyrazines; D019089:Stem Cell Factor; D000069286:Bortezomib